论文部分内容阅读
目的观察雷贝拉唑联合氟哌噻吨美利曲辛治疗慢性胃炎的临床效果。方法将108例慢性胃炎患者,随机分为观察组和对照组各54例,对照组给予雷贝拉唑联合铝碳酸镁治疗,观察组在对照组基础上联合氟哌噻吨美利曲辛进行治疗,比较2组临床疗效及治疗前后患者胃肠道症状评分及焦虑抑郁情绪评分变化,随访1年,观察2组患者的复发状况。结果观察组治疗总有效率94.44%,高于对照组的79.63%,差异有统计学意义(P<0.05)。治疗后,2组患者胃肠道症状评分与焦虑抑郁情绪评分均低于治疗前,且观察组评分低于对照组,差异均有统计学意义(P<0.05)。观察组1年复发率为5.56%低于对照组的14.81%,差异有统计学意义(P<0.05)。结论取雷贝拉唑联用氟哌噻吨美利曲辛治疗慢性胃炎采的临床效果显著,改善患者的症状,且复发率低,值得临床推广使用。
Objective To observe the clinical efficacy of rabeprazole combined with flupenthixol and melitracen in the treatment of chronic gastritis. Methods 108 patients with chronic gastritis were randomly divided into observation group and control group, 54 cases in each group. The control group was treated with rabeprazole combined with aluminum magnesium carbonate. The observation group was treated with flupentixol and melitracen on the basis of the control group The clinical efficacy, gastrointestinal symptom scores and anxiety and depression scores of two groups were compared before and after treatment. The patients were followed up for 1 year and the relapse status was observed. Results The total effective rate of observation group was 94.44%, which was higher than 79.63% of control group, the difference was statistically significant (P <0.05). After treatment, the gastrointestinal symptoms scores and anxiety and depression scores of two groups were lower than those before treatment, and the score of the observation group was lower than that of the control group (P <0.05). The 1-year recurrence rate in the observation group was 5.56% lower than that in the control group (14.81%), the difference was statistically significant (P <0.05). Conclusions The rabeprazole combined with flupentixol and melitracen in the treatment of chronic gastritis has significant clinical effect and improves the symptoms of patients with low recurrence rate, which is worthy of clinical promotion.